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BIOCOMPATIBLE NANO RARE EARTH
OXIDE UPCONVERTERS FOR IMAGING
AND THERAPEUTICS

Metal fluorides, oxysulfides and phosphates are the matrices widely used to study the up conversion process and only
a few reports are available with oxides. However, in order to
have biocompatibility, a silica layer has been often coated on
the surface of up conversion phosphors. Among the rare earth
oxides, cerium oxide nanoparticles (CNPs) are shown to be
biocompatible and exhibit regenerative antioxidant properties.
Earlier studies by co-inventors indicate that cerium oxide
nanoparticles offer carbonic anhydrase inhibition, protection
of primary cells from the detrimental effects of radiation
therapy, prevention ofretinal degeneration induced by intracellular peroxides, and neuroprotection to spinal cord neurons and have radical scavenging properties. By tailoring the
surface potential or conjugating with targeting agents, specific uptake of cerium oxide nanoparticles in cells can be
achieved. Although enhanced cellular uptake has been optimized based on surface characteristics, the mechanism of
interaction, absorption and metabolism of these nanomaterials under in vivo condition is poorly understood.
The interaction of cerium oxide nanoparticles with cells
and tissues needs to be well established for biomedical applications. Through real time imaging of cell-nanoparticle interactions it is possible to better understand the complex processes and conditions that facilitate or inhibit the uptake and
release of materials into the cytosol or other intracellular
targets. But, cerium oxide nanoparticles show weak emission
characteristics in visible region, inhibiting the direct use of
these materials for imaging purposes. One of the approaches
to enhance the emission of cerium oxide nanoparticles is by
doping with europium which has strong emission in the visible region. But, combining the non-toxic, biocompatible
properties of cerium oxide nanoparticles with up conversion
dopants would be a novel approach to optimize the emission
properties. However, it is important to assess the interaction
between the nanoparticles and cells since the biocompatibility and cellular uptake properties determine the therapeutic
and imaging applications.
The present invention focuses on the formulation of codoped cerium oxide nanoparticles with Yb 3 + sensitizer and
mainly Er3 + as an emitter. These co-doped, annealed cerium
oxide nanoparticles will hereafter be referred to as up conversion nano ceria (UNC). In order to demonstrate the emission wavelength tunability, the emitter ion was changed to
Ho 3 + or Tm 3 +. The physical and optical properties of up
conversion nano ceria and characteristics of these novel materials in various cells (A549, WI-38, HUVEC) were investigated by the co-inventors. In order to assess the antioxidant
properties, catalase mimetic activity to catalyze the decomposition of hydrogen peroxide into water and oxygen was
studied. The influence of nanoparticle interaction on the cell
viability ofnormal lung fibroblasts (CCL-135) and cancerous
cells (CRL-5803) were analyzed.

This application claims the benefit of priority to U.S. Provisional Application No. 61/081,903 filed on Jul. 18, 2008
and was funded in part by National Science Foundation
Nanoscale Interdisciplinary Research Teams (NSF NIRT)
(0708172 CBET) and National Institutes of Health (NIH)
ROI (1R01AG031529-01).
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FIELD OF THE INVENTION
This invention relates to nanoparticles and, in particular, to
methods and systems for up-converter tagged nanoparticles
and up conversion nano cerias for site selective drug delivery
and treatment of diseases.
BACKGROUND AND PRIOR ART
Understanding the complex spatio-temporal interplay of
nanomaterials used as therapeutics at the cellular to the
molecular level is required for designing nanoparticle based
therapeutics and biomarkers for many diseases. To study
these interactions, fluorescent labeling is commonly used for
both in vivo cellular imaging and in vitro assay detection.
Conventional fluorescence imaging involves single photon
excitation of higher energy to emit lower energy light, a
process known as down conversion. Organic dyes, metal and
semiconductor nanoparticles are widely used as fluorophores
to follow ligands into the cells and within tissue in animals as
described in Michalet X, Pinaud F, Bentolila L, Tsay J, Doose
S, Li J, Sundaresan G, Wu A, Gambhir S, Weiss S. Quantum
Dots for Live Cells, in Vivo Imaging, and Diagnostics. Science 2005; 307, pp. 538-544. The fluorophores suffer from
auto-fluorescence from biological tissues, photobleaching,
low signal-to-noise ratio, potential damage to DNA and cell
death as described in Green M, Howman E. Semiconductor
quantum dots and free radical induced DNA nicking. Chem
Commun 2005, pp. 121-123 and in Riegler J, Nann T. Application of luminescent nanocrystals as labels for biological
molecules. Anal Bioanal Chem 2004, 379, pp. 913-919.
Up conversion phosphors (UCPs) capable of converting
near infrared (NIR) radiation into shorter wavelengths
through a multi-photon process, offers an alternative with
minimal photo damage and auto-fluorescence due to the noninvasive nature oflight as described inAuzel F. Upconversion
and Anti-Stokes Processes with f and d Ions in Solids. Chem
Rev 2004, pp. 139-173. Since up conversion occurs within the
host crystal and is therefore less affected by the chemical and
biological environments, and allows synthesis of materials
without the loss of surface chemical reactivity.
All these favorable properties indicate that there is a real
potential for the development of up conversion phosphors in
the analysis of biological samples, especially for fluorescent
imaging in vivo. Up conversion phosphors contain a sensitizer ion which absorbs the near infrared photons and transfers the absorbed energy sequentially to excite an emitter ion
into a state which then emits in the visible. Lanthanide ions
are particularly suitable candidates for up conversion processes because of their energy level structure providing many
intermediate levels with favorable spacings and long-lived
excited states. Yb 3 + ions have been widely used as sensitizer
as Yb 3 + ions exhibit a relatively large absorption cross section
in the near infrared region allowing excitation with laser
diodes.
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SUMMARY OF THE INVENTION
A primary objective of the invention is to provide methods,
apparatus and systems for doping cerium oxide and other
therapeutically valuable nanoparticles with rare earth ions
either singly or in combinations so that infrared light is
absorbed and visible light is emitted through the process of up
convers10n.
A secondary objective of the invention is to provide a novel
type of therapeutic nanoparticle with rare earth doping to
provide for up conversion emission for tracking and evaluating the functionality of the nanoparticles and further elucidation of ROS scavenging mechanism.
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A third objective of the invention is to provide methods,
FIG. Sa shows up conversion nano ceria absorbed by
apparatus and systems for using up converting rare earth
human cells of A549 in a culture under ambient light.
nanoparticles to locate and estimate their presence in cells for
FIG. Sb shows up conversion nano ceria absorbed by
finding, tracking and evaluating the therapeutic functionality
human cells of A549 in a culture under ambient light plus
of nanoparticles and other therapeutic agents in biological
infrared laser excitation.
systems.
FIG. Sc shows up conversion nano ceria absorbed by
A first embodiment provides a method of doping a cerium
human cells of HUVEC in a culture under ambient light.
oxide nanoparticle with one or more dopants to form coFIG. Sd shows up conversion nano ceria absorbed by
doped up conversion nanoparticle ceria, at least one of the
human cells ofHUVEC in a culture under ambient light plus
dopants absorbing infrared light and emitting visible light 10 infrared laser excitation.
FIG. Se shows up conversion nano ceria absorbed by
through the process of up conversion. The dopants are
human cells ofWI-38 in a culture under ambient light.
obtained from one or more nitrates selected from the group
including ofYb, Er, Ho, Tm and Pr, such as co-doping Yb with
FIG. Sf shows up conversion nano ceria absorbed by
one or more nitrates from the group consisting of Er, Ho, Tm
human cells ofWI-38 in a culture under ambient light plus
and Pr, doping a cerium oxide nanoparticle with one ofYb 3 + 15 infrared laser excitation
and Er3+, or adding one of Er+, Ho 3 + and Tm3 + to the Ce0 2
FIG. 6a is a graph showing the conversion of hydrogen
nanoparticle. In an embodiment the up conversion nanoparperoxide to oxygen was followed by measuring decreases in
ticle ceria are Er, Yb doped Ce0 2 particles. Applications
hydrogen peroxide levels via ultraviolet absorption showing
include using the up converting nano ceria nanoparticles to
catalase mimetic activity.
locate cells using the up converting nano ceria nanoparticles 20
DESCRIPTION OF THE PREFERRED
for finding, tracking and evaluating therapeutic agents in
EMBODIMENTS
biological systems.
Beyond Yb oxides, the embodiments also contemplate as
Before explaining the disclosed embodiments of the
up conversion sensitizer dopants metal oxides selected from
the group including but not limited to La, Nd, Gd and Eu rare 25 present invention in detail it is to be understood that the
invention is not limited in its application to the details of the
earth metal oxides.
particular arrangements shown since the invention is capable
As another embodiment, a cerium oxide nanoparticle is
of other embodiments. Also, the terminology used herein is
co-doped with a rare earth oxide selected from the group
for the purpose of description and not of limitation.
consisting of La, Nd, Gd and Eu with Yb sensitizer and Er as
30
Prior up-conversion patents include U.S. Pat. No. 5,089,
an emitter.
860 issued to Deppe et al, on Feb. 18, 1992, U.S. Pat. Nos.
The cerium oxide nanoparticle can be co-doped with an
6,327,074 and 6,501,590 issued to Bass et al. respectively on
up-converting material to form an up conversion nano ceria
Dec. 4, 2001 and Dec. 31, 2002, U.S. Pat. No. 6,654,161
that absorbs infrared light and emits visible light through the
issued to Bass et al. on Nov. 25, 2003, U.S. Pat. No. 6,844,387
process of up conversion including emitting one of a red, a
35 issuedtoBassetal.onJan.18,2005, U.S. Pat.No. 7,075,707
green and a blue light.
issued to Rapaport et al. on Jul. 11, 2006 and U.S. Pat. No.
Further objects and advantages of this invention will be
7 ,4 71,306 issued on Dec. 30, 2008 having a common inventor
apparent from the following detailed description of preferred
and assigned to the same assignee as the subject invention are
embodiments which are illustrated schematically in the
incorporated herein by reference hereto.
accompanying drawings.
40
U.S. patent application Ser. No. 12/365,971 filed on Feb. 5,
2008; Ser. Nos. 12/124,620 and 12/124,234 filed on May 21,
BRIEF DESCRIPTION OF THE FIGURES
2008, Ser. No. 12/349,712 filed on Jan. 7, 2009, Ser. No.
12/365,971 filed on Feb. 5, 2009 and61/180,475 filed on May
FIG. 1 is a block diagram of the experiment used to determine the emission spectra of the samples.
22, 2009 each having a common inventor and which are
FIG. 2a is a HRTEM micrograph showing up conversion 45 assigned to the same assignee as the subject invention, are
nano cerias with a size in the range between approximately 20
also incorporated herein by reference hereto.
to approximately 40 nm. The inset shows the selected area
The present invention relates to the synthesis of rare earth
electron diffraction pattern that shows the presence of fluorite
co-doped cerium oxide nanoparticles having strong NIR-tostructure.
visible up conversion fluorescence. The tunability of emisFIG. 2b is a HRTEM micrograph showing up conversion 50 sion wavelength was studied with respect to co-dopant chemnano cerias with a size in the range of approximately 20 nm.
istry on excitation with the wavelength of 975 nm. Cellular
FIG. 2c shows an EDAX spectrum of the nano particle
uptake of nanoparticles in A549, WI-38 and HUVEC cells
showing the presence of Ce, Yb, Er and 0 along with C and
was followed with NIR excitation and cytotoxicity of the
Cu.
particles were assessed by using MTT and LDH assay. AntiFIG. 2d shows an x-ray diffraction pattern that indicates the 55 oxidant catalase mimetic activity of nanoparticles was folretention of fluorite structure of ceria.
lowed by the decomposition of hydrogen peroxide. Cell
FIG. 3a shows the optical absorption spectrum of up conviability of normal lung fibroblasts and lung cancer cells with
.
.
vers10n nano cena.
nanoparticle was investigated to ascertain the interaction of
nanoparticle with normal and cancerous cells. The results
FIG. 3b shows the measured emission spectra of samples.
FIG. 3c shows the measured emission decay dynamics of 60 from this study revealed that the biocompatible, co-doped
the red light emitted from the up conversion nano ceria.
cerium oxide nanoparticles exhibited strong up conversion
FIG. 4a shows up conversion nano cerias are not toxic in
properties which can be utilized for real time tracking of
cell culture models of A549.
nanoparticles such as in cellular uptake as well as in biocataFIG. 4b shows up conversion nano cerias are not toxic in
lytic activity, demonstrating the potential applications in cancell culture models ofWI-38.
65 cer therapy.
FIG. 4c shows up conversion nano cerias are not toxic in
The present invention focuses on the formulation of codoped cerium oxide nanoparticles with Yb 3 + sensitizer and
cell culture models of HUVEC.
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mainly Er3 + as an emitter. These co-doped, annealed cerium
oxide nanoparticles will hereafter be referred to as up conversion nano ceria (UNC). In order to demonstrate the emission wavelength tunability, the emitter chemistry was
changed to Ho 3 + or Tm3 +. The physical and optical properties
of up conversion nano ceria and characteristics of these novel
materials in various cells including A549, WI-38, and
HUVEC were investigated by the co-inventors. In order to
assess the antioxidant properties, catalase mimetic activity to
catalyze the decomposition of hydrogen peroxide into water
and oxygen was studied. The influence of nanoparticle interaction on the cell viability of normal lung fibroblasts (CCL135) and cancerous cells (CRL-5803) were analyzed.
Experimental Data:
Analytical grade nitrates of Ce, Yb, Er, Ho and Tm from
Sigma-Aldrich Chemical Inc. were used for synthesis of up
conversion nanophosphors. Ammonia solution (IN Alfa
Aesar) was added to aqueous nitrate solutions of Ce 3 + (0.1
M), Yb 3 + (20%) and Er3 + (2%) to maintain the pH above 10.
The resultant precipitate was washed, armealed at 900° C. and
filtered through 100 nm membrane filter, referred as up conversion nano ceria. A similar procedure was used to synthesize Ce0 2 :20% Yb, 2% Ho and Ce0 2 :20Yb %, 0.5% Tm.
The powders were characterized by X-ray diffraction
(Rigaku) and high resolution transmission electron microscopy (Tecnai F30) to evaluate the structure and size. The
optical absorption spectrum was recorded with Cary 500
Spectrophotometer. A diode laser emitting at 975 nm was
used was used for the luminescence and time decay studies.
Only up conversion nano cerias were used for imaging and
therapeutic property assessment.
A549, WI-38, CRL-5803, and CCL-135 were obtained
fromAmerican Type Culture Collection (Manassa, Va., USA)
and Human Umbilical Vascular Endothelial Cells (HUVEC)
cells were obtained from Lonza Walkersville, Inc. (Walkersville, Md., USA).A549, CRL-5803, andCCL-135 cells were
cultured in Dulbecco's modification of Eagle's medium
(DMEM) (Mediatech, Inc, Manassa, Va., USA) supplemented with 10% fetal bovine serum (FBS) (Equi-tech Bio,
Kerrville, Tex., USA) and 100 IU mL- 1 penicillin (Mediatech, Inc, Manassa, Va., USA). WI-38 cells were cultured in
Eagle's Minimum Essential Medium (EMEM) supplemented
with 10% FBS and 100 IU mL- 1 penicillin. HUVEC cells
were cultured in Endothelial Cell Medium (ECM) (ScienceCell, San Diego, Calif., USA) supplemented with 5% FBS
and 100 IU mL- 1 penicillin. All cultures were maintained at
37° C. in a humidified incubator under a 5% atmosphere of
C0 2 .
Cells were cultured in 96-well culture dishes using appropriate media conditions and treated with up conversion nano
cerias in varying concentrations; 0, 50, 250, 500, 750, 1000
µMand incubated for 24 hat 37° C. MTT dye (3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Amresco, Solon, Ohio, USA) was added to a final 1.2 mM concentration and cells were incubated another 4 hours at 37° C.
To solubulize the dye, cells were lysed (10% SDS, 0.01 M
HCl) and incubated overnight at 37° C. Absorbance was
measured at 570 nm using a SpectraMax 190 spectrophometer (Molecular Devices, Surmyvale, Calif., USA). Cell proliferation was determined by dividing the absorbance of
treated samples to untreated controls and reported as a percentage. Lactate dehydrogenase (LDH) release was measured in presence of up conversion nano ceria using Cytotoxicity Detection KirLus (LDH) (Roche Diagnostics,
Germany). In short, supernatants from each well was collected and spun to remove cell cellular debris. Freshly prepared reaction mixture was added, incubated for 15 min at RT

protected from light. Stop solution was added and absorbance
was measured at 490 nm. LDH release was determined as
percentage of untreated control samples.
All samples for microscopy were prepared as follows.
Cells were grown to approximately 60-70% confluence. After
24 hour treatment with various up conversion nano ceria
concentrations, cells were washed 2 times in appropriate
saline (A549 and WI-38, Dulbeccos's Phosphate Buffered
Saline, (Mediatech, Inc, Manassa, Va., USA), HUVEC,
Hepes Buffered Saline without Phenol Red, (Lonza Walkersville, Inc., Walkersville, Md., USA), trypsinized and transferred to glass coverslips. After a further 24 hour growth, cells
were washed 2 times in appropriate saline, fixed in cold (20°
C.) methanol for 10 min at RT then washed 2 times with
sterile water.
All spectrophotometric data was collected using a 40 µL
quartz cuvette with a 1 cm path length in a Hewlett-Packard
diode array UV-visible 8453 spectrophotometer. Reactions
were carried out in assay buffer containing 50 mM Tris, pH
7.5 and 1 mM diethylenetriaminepentacetic acid (DTPA) to
chelate any possible adventitious metal. Hydrogen peroxide
(Acros Organics) was added to start the reaction and samples
were analyzed for a total of 600 seconds with a cycle time
(time point) of 0.5 seconds at a wavelength of 240 nm. Up
conversion nano ceria preparations were reconstituted in H 2 0
to initial concentration of 10 µM and ultrasonicated for 45
min before use.
To evaluate the size of up conversion nano cerias, high
resolution transmission electron microscopic (HRTEM)
studies were carried out. In the as prepared condition size of
the nanoparticle was found to be in the range of7-10 nm. In
the experiment, the size of the nanoparticle was between
approximately 7 and approximately 10 nm while the mean
crystallite size was calculated to be approximately 8.4 nm.
Lattice parameter was found to be approximately 0.5423 nm
in the as prepared condition and decreased to 0.5412 nm upon
annealing. Cerium can exist in either +3 or +4 oxidation
states. In the nano scale the concentration ofCe 3 increases. As
a result of higher ionic radii of Ce3 + (0.1143 nm) than Ce4 +
(0.97 nm), the lattice parameter is larger than that ofbulk ceria
(0.541 nm). Further, trivalent Yb and Er dopant ions have
higher ionic radii (0.0985 nm and 0.1004 nm, respectively)
than that of Ce4 +. As a result prepared nanoparticles have
higher lattice parameter than that of bulk ceria. On armealing
Ce 3 + concentration decreases leading to a reduction in the
lattice parameter.
Since the nanoparticle was in the form of a powder, a strip
of dual sided transparent tape was placed on a glass slide and
the particles were sprinkled on the exposed sticky side of the
tape. This resulted in a sample that could be placed in the
spectrophotometer so that its absorption spectrum could be
measured. The absolute value of the absorption strength was
not critical to the project but the absorption spectrum was and
such samples enabled absorption spectra measurements. The
emission spectra of co-doped cerium oxide nanoparticles
were measured using the apparatus shown in FIG. 1. This
procedure had been developed in prior research (A. Rapaport,
J. Milliez, M. Bass, A. Cassanho, H. Jenssen, J. of Display
Technology 2006, 2, 68).
A diode laser emitting at 97 5 nm excited samples placed in
the integrating sphere as indicated. The particles being studied were confined in a small cavity at the center of a clear
cabochon. In FIG. 1, the metal mirror indicated in the block
diagram was removed so that the green emission from a
sample could be photographed. An integrating sphere and
Instrument Systems CAS 140B spectrometer enabled collecting the emitted light and measurement of its spectrum. For
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decay studies, a Spectra Physics MOPO laser generating
pulses at approximately 975 nm of about 4 nsec duration at
approximately 10 Hz pulse repetition frequency was used to
excite the samples and enable measurement of the emission
decay dynamics. The emitted light was directed through a 97 5
nm blocking filter to a fast detector (Hamamatsu PMT
H6780-20 with sub 1 nsec rise time) which was connected to
a Tektronix 2440 oscilloscope (FIG. 2b ). The recorded decays
were stored digitally and later analyzed with Origin software.
Equipment was set up for the experiment to detect the
nanoparticles when viewed through the microscope. First up
conversion nano cerias were placed on a microscope slide
and, when excited by the 975 nm light from the diode laser,
were seen to emit red light. Then the particles were placed in
a cell culture and when exposed to 975 nm light could be
detected and distinguished easily from other black spots in
the field of view. The doped nanoparticles were those black
spots that emitted red light when exposed to the diode laser
light as shown in FIGS. Sa through Sf The images were
captured by a CCD camera when the excitation is on and the
emitting nanoparticles were seen as the red emitting items in
the displayed image. To protect an experimenter from inadvertently being exposed to 975 nm laser light, the beam path
was placed in an enclosure and a filter that blocked 975 nm
light was placed in the microscope optics before any light
could reach either the eyepieces or the CCD camera.
FIG. 2 shows the characterization of up conversion nano
cerias. FIG. 2a is a HRTEM micro graphs showing up conversion nano cerias with a size range of approximately 20 to
approximately 40 nm. The inset in FIG. 2a shows the SAED
pattern from A to D corresponding to (111), (200), (220) and
(311) planes. The HRTEM in FIG. 2b shows up conversion
nano cerias having the primary particle size of approximately
20 nm. The interplanar distance corresponds to (111) plane of
flurite structured ceria. The EDAX spectrum of the nanoparticle in FIG. 2c shows the presence of Ce, Yb, Er and 0 along
with C and Cu which comes from TEM grid. In FIG. 2d, the
X-ray diffraction pattern indicates the retention of fluorite
structure of ceria even upon armealing (JCPDS card No.
81-0792).
On annealing, up conversion nano cerias have a primary
particle size of about 20 nm along with a few particles in the
size range of 40 nm, as a result interfusion to form larger
particles due to annealing as shown in FIGS. 2a and 2b.
Selected area electron diffraction (SAED) pattern shows the
presence of fluorite structure as shown in the inset in FIG. 2a.
Although the core particles still retained the nano size, the
presence of few larger agglomerates is evident after filtration.
From Energy dispersive analysis of X-rays as shown in FIG.
2c and X-ray diffraction shown in FIG. 2d, it can be coneluded that Yb 3 + and Er3+ were doped into the matrix of
cerium oxide nanoparticles and hence no modification in
diffraction pattern.
Previous studies of up conversion showed that fluoride
crystals co-doped with Yb 3 + ions absorb light near 975 nm
and then efficiently emit visible light depending on the codopant nature, Thus, the first step in optically characterizing
up conversion nano cerias was to determine the Yb 3 + absorption spectrum in cerium oxide nanoparticles host. Details of
the experimental set up used for optical property measurement were previously described.
FIG. 2a is a graph showing the optical absorption spectrum
of up converter nano ceria and FIG. 2b shows the measured
emission spectra of samples of (A) up converter nano ceria,
(B) Ce0 2 :20Yb %, 2% Ho and (C) Ce0 2 :20% Yb, 0.5% Tm.
The transition 4 F912 --;. 4 I512 lead to red emission in up converter nano ceria with a small amount of green light (around

540 nm 4 S312 --;. 4 I512 transition) due to Er3+. On co-doping
with Ho 3 + green emission appears as a result of 5 F4 , 5 S2 --;. 5 I 8
transition along with weak red light. Tm3 + co-doping results
in weak blue emission (1G4 --;. 3 H 6 ) due to reduced probability
for multi photon transition; inset demonstrates the red emission from up converter nano ceria observed from an optical
microscope under NIR excitation. Scale bar in the inset corresponds to 10 µm. FIG. 3c is a graph showing the measured
emission decay dynamics of the red light emitted from up
converter nano ceria. The solid line is an exponential decay fit
with decay time of 10.6 µsec. On near infra red excitation
(975 nm), emission wavelengths can be tuned from red, green
or blue on varying the co-dopant chemistry from Er3 +, Ho 3 +
or Tm3 +, respectively.
From this data it is clear that the Er3+ ions in cerium oxide
nanoparticles emit principally in the red emission between
approximately 640 and approximately 700 nm while Ho 3 +
co-doping results in the green emission between approximately 530 and approximately 570 nm. Samples with Tm 3 +
as the co-dopant were expected to emit blue light but the
emission, if any, was too weak due to lower probability of
multiphoton process. Up conversion nano ceria powders with
Yb 3 + and Er3 + co-dopants when excited by approximately
975 nm light from the diode laser could be easily seen to emit
red light.
In earlier studies using fluoride hosts, the decay dynamics
indicate a fluorescent lifetime ofabout 3 ms compared to 10.6
µs for up conversion nano ceria. A very short emission time
observed in the present work indicates the presence of significant fluorescence quenching. Since oxide matrices have
higher phonon energy than the fluorides this strong quenching is not surprising. In spite of quenching, the up conversion
emission intensity is sufficient to utilize the water dispersible
up conversion nano cerias as potential biomarkers. Thus, the
emission color can be tuned from red, green or blue by varying the co-dopant from Er3 +, Ho 3 + and Tm3 +, respectively.
Recently several studies have shown that cerium oxide
nanoparticles have potential for use as a biological antioxidant but opinion on toxicity of cerium oxide nanoparticles in
cell culture models differs. As a result, although up conversion cerias have visible emission, the important step towards
the biomedical application is to assess the toxicity in a wide
range of concentrations. For the studies resulting in the
present invention, the co-inventors chose several cell culture
models includingA549 adenocarcinoma cells, WI-38 human
lung fibroblasts and Human Umbilical Vein Endothelial
cells-HUVECs. The toxicity by the metabolic reduction of
a tetrazolium dye (MTT) or by the release oflactate dehydrogenase (LDH) was assessed. By gauging cell viability using
two independent methods, the co-inventors were confident
that the cells are indeed viable under the experimental conditions.
When exposed to nanomolar and micromolar concentrations of materials, no significant toxicity was observed in
A549 or WI-38 cells as shown in the graphs shown in FIG. 4a
and FIG. 4b, respectively. Some toxicity was observed in
HUVECs in a dose dependent marmer when viability was
determined by MTT assay, however no significant release of
LDH occurred, suggesting the material caused a decrease in
cellular metabolic rate without lysis of the cell membrane as
shown in the graph of FIG. 4c.
Toxicity results indicate that up conversion nano ceriums
are not toxic in cell culture studies, a key finding for their
potential use in biomedical applications. In order to visualize
up conversion nano ceriums in a biological model, the above
mentioned model cell types were exposed in cultured monolayers to varying doses of up conversion nano ceriums, and
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observed a concentration-dependent increase in visible light
emission when cells were excited using light at a wavelength
of approximately 97 5 nm. An experimental set up was used to
detect up conversion nano ceriums through the microscope.
Particles were exposed to the culture models for 24 hours,
cells were harvested by trypsin digest of extracellular matrix
and then subsequently rep lated in culture dishes to form again
a monolayer. Up converter nano cerias are absorbed by several human cells in culture.
Cells of A549 are shown in FIGS. Sa and Sb, HUVEC are
shown in FIGS. Sc and Sd and WI-38 are shown in FIGS. Se
and Sf, in the presence of ambient light in FIGS. la, Sc and Sf
and near infrared excitation in FIGS. Sb, Sd and S/with a
wavelength of approximately 975 nm, approximately 4 ns
pulse rate, approximately 10 Hz pulse repeat rate and a pump
power of approximately 170 mW. Cells were incubated with
cell monolayers for 16 hours in the presence of 100 µM up
converter nano ceria. Cells were subsequently removed by
trypsination from the monolayer to exclude loosely bound
and excess up converter nano cerias, washed extensively in
phosphate buffer solution, and rep lated on glass cover slips in
6-well tissue culture dishes. After 16 hours further incubation
to allow for monolayer formation cells were fixed and
observed by optical microscopy and the scale bar corresponds
to 50 µm.
The image captured by the CCD camera when the excitation is on is shown in FIGS. Sb, Sd and Sf and the emitting
nanoparticles can be seen as the red emitting items in the
image. Arrows represent few of the particles which highlight
under near infrared excitation. These images comprise only
the replated cells, the results strongly suggest the up conversion nano cerias are intracellular and not simply loosely
bound material to cells. The particles are somewhat larger,
suggesting that agglomeration is likely to take place inside the
cells after absorption although cellular uptake of agglomerated up conversion nano ceria is also possible. The aggregation of CNPs inside cells was shown in prior work by coinventors using TEM studies depending on the surface
potential of cells and nanoparticles.
Cellular uptake of smaller as well as larger (agglomerates)
particles have also been reported. Transport of small particles
primarily occurs by diffusion and endocytosis, while uptake
oflargerparticles could be facilitated by sedimentation on the
culture monolayer. Although the current optics used to image
this particles have shown mostly agglomerated particles, still
there may be the presence of finer particles which may be too
weak to be observed with nanometer resolution using the
experimental capabilities.
Co-inventors have previously shown that cerium oxide
nanoparticles can scavenge free radicals and mimic enzymatic antioxidants such as superoxide dismutase and catalase. Since up conversion nano cerias are biocompatible, biological catalytic activity was tested for potential biomedical
applications. Catalse mimetic activity of up conversion nano
cerias were followed by monitoring the peroxide levels using
ultraviolet-visible spectrophotometry. FIG. 6a illustrates the
role of up converter nano cerias in catalase mimetic activity
and cancer treatment. FIG. 6a shows the conversion of hydrogen peroxide to oxygen was followed by measuring decreases
in hydrogen peroxide levels via ultraviolet absorption (absorbance maximum at 240 nm). A representative experiment
with at least three independent samples is shown, and the
experiment was repeated at least two times on two preparations of cerium oxide nanoparticles. Data plotted represent
the mean of at least three samples and the error plotted is the
standard deviation of the mean.

The kinetics of these reactions was determined by measuring the decrease in absorbance of hydrogen peroxide at
approximately 240 nm. In presence of 100 µM up conversion
nano ceria, concentration of hydrogen peroxide reduced with
time as shown in FIG. 6a. From this observation, it is evident
that up conversion nano cerias are catalase mimetics, i.e. they
convert hydrogen peroxide to molecular oxygen (0 2 ).
Although the mechanism of this activity is still under study,
it could be due to radical scavenging properties of cerium
oxide nanoparticles that have been recently reported by several groups. In order to investigate the effect of up conversion
ceria on cancer cell proliferation in vitro, cell viability of
cancerous lung cells (CRL-5803) and normal lungs fibroblasts (CCL-135) were tested with various nanoparticle concentrations. Cell viability of both of the cells was measured
72 hours post exposure to various concentrations of up conversion nano ceria. In the case ofCRL-5803, proliferation of
cancerous lung cells decreased by approximately 33.7%
(p<0.0001) when exposed to approximately 100 nM of up
.
.
convers10n nano cena.
To determine if this decrease in cell proliferation and
viability was due to an increase in the activation of apoptosis,
caspase-3/7 activity was measured 72 hours post up conversion nano ceria exposure. Caspase-3/7 activity increased by
approximately 56.6% (p=0.012) when exposed to approximately 100 nM up conversion nano ceria. Under similar conditions, proliferation of normal lung fibroblasts increased by
approximately 21.5% (p=0.0178) when exposed to approximately 100 nM up conversion nano ceria. To determine if this
increase in cell viability was due to a decrease in the activation of apoptosis, caspase-3/7 activity was measured approximately 72 hours after up conversion nano ceria exposure.
Caspase-3/7 activity did not significantly change in normal
lung fibroblasts that were exposed to the various concentrations of up conversion nano ceria.
Recently co-inventors reported that under in vitro conditions, the cellular uptake of nanoparticles differs between a
normal versus a tumor cell and can be attributed to the difference in intercellular activity, as well as cell structure. As a
result of regenerative antioxidant properties of up conversion
nano ceria, nanoparticles may reduce the proliferation of
cancer cells. Nonetheless, recent studies on ZnO and Ti0 2
show that these nanoparticles exert cancer killing activity
through the reactive oxygen species generation or surface
interaction with cells.
Recently, it has been reported that europium hydroxide
nanorods show pro-angiogenic properties due to the formation of reactive oxygen species in a concentration dependent
manner.
Based on the above facts, it is expected that up conversion
nano cerias affect the equilibrium oxygen concentration of
the cells in a cell specific reaction. In the case of cancerous
cells it probably generates reactive oxygen species which
annihilates the cancerous cells while enhancing the normal
cell proliferation.
In conclusion, for biomedical application of up conversion
nanoparticles, studies on toxicity are of considerable importance to understand the properties and potential applications.
In this study conducted for the present invention, co-doped
cerium oxide nanoparticles were synthesized by precipitation
technique. Up conversion nano cerias that are biocompatible
have shown to be a potential biomarker with antioxidant
properties. Up conversion nano cerias interact in a cell specific manner preventing cancer cell proliferation while protecting normal cells, which can have a far reaching impact in
future cancer research. With suitable surface targeting
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ligands, up conversion nano cerias could be used for site
selective drug delivery for the treatment of diseases like cancer.
In summary, a first embodiment provides a method of
doping a cerium oxide nanoparticle with one or more dopants
to form co-doped up conversion nanoparticle ceria, at least
one of the dopants absorbing infrared light and emitting visible light through the process of up conversion. The dopants
are one or more nitrates selected from the group including of
Yb, Er, Ho, Tm and Pr, such as co-doping Yb with one or more
nitrates from the group consisting of Er, Ho, Tm and Pr,
doping a cerium oxide nanoparticle with one of Yb 3 + and
Er3+, or adding one of Er3+, Ho 3 + and Tm3 + to the Ce0 2
nanoparticle. in an embodiment the up conversion nanoparticle ceria are Er, Yb doped Ce0 2 particles. Applications
include using the up converting nano ceria nanoparticles to
locate cells using the up converting nano ceria nanoparticles
for finding, tracking and evaluating therapeutic agents in
biological systems. The cerium oxide nanoparticle can be
co-doped with an up-converting material to form an up conversion nano ceria that absorbs infrared light and emits visible
light through the process of up conversion including emitting
one of a red, a green and a blue light.
While the invention has been described, disclosed, illustrated and shown in various terms of certain embodiments or
modifications which it has presumed in practice, the scope of
the invention is not intended to be, nor should it be deemed to
be, limited thereby and such other modifications or embodiments as may be suggested by the teachings herein are particularly reserved especially as they fall within the breadth
and scope of the claims here appended.

conversion nanoceria emitters that absorb infrared light
and emit a red, a green or a blue light through the process
of up conversion.
2. A biocompatible non toxic up conversion nanoparticle
consisting essentially of:
a cerium oxide nanoparticle doped with Yb 3 +as a sensitizer
and Ho 3 + as an emitter to form up conversion nano ceria
that absorbs infrared light and emits visible light through
the process of up conversion to emit red light as a biocompatible non toxic nano rare earth up conversion for
imaging and therapeutics.
3. An up conversion nanoparticle consisting essentially of
a doped nano ceria based up conversion material consisting
essentially of:
a ceria base material;
a Yb sensitizer dopant ion doped into the ceria base material; and
at least one emitter dopant ion selected from the group
consisting of Ho, Tm and Pr emitter dopant ions, also
doped into the ceria base material.
4. The nanoparticle of claim 3 wherein the doped nano
ceria based up conversion material absorbs in the infrared
wavelength range and emits in the visible wavelength range.
5. The nanoparticle of claim 4 wherein the nano ceria based
up conversion material emits in the red portion of the visible
wavelength range.
6. The nanoparticle of claim 4 wherein the nano ceria based
up conversion material emits in the green portion of the visible wavelength range.
7. The nanoparticle of claim 4 wherein the nano ceria based
up conversion material emits in the blue portion of the visible
wavelength range.
8. An up conversion nanoparticle selected from the group
consisting ofCe02:20% Yb, 2% Ho and Ce02:20% Yb, 0.5%
Tm.
9. The up conversion nanoparticle of claim 3 wherein a size
of the nanoparticle is from about 7 to about 10 nanometers.
10. The up conversion nanoparticle of claim 3 wherein a
latticeparameterofthenanoparticleis from 0.5412 to 0.5423.

We claim:
1. An up conversion nano ceria for site selective drug
delivery and treatment of disease consisting essentially of:
a water dispersible non toxic up conversion nano ceria
consisting essentially of:
a cerium oxide nanoparticle doped with Yb ions and at least
one of an upconverting Ho, Tm, and Pr ion to form up
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